Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod vs placebo in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
jRCT2080221916Phase 3
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Fingolimod 0.5 mg with Placebo (2 arms).
02
Drugs
fingolimod
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCT2080221916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221916.